Immunotherapy atezolizumab limits disease progression for patients with mUBC

Data shows potential for first new treatment modality in over 30 years

Source: Pharmacy Europe - September 27, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Research atezolizumab IMvigor 210 Latest News metastatic urothelial bladder cancer mUBC Source Type: news